Form 4: Cyclo Therapeutics Officer Acquires Stock Options
SEC Form 4 Filing
Michael Eric Lisjak, Chief Regulatory Officer of Cyclo Therapeutics, Inc., reports the acquisition of stock options.
Summary
- Michael Eric Lisjak, Chief Regulatory Officer of Cyclo Therapeutics, Inc. (CYTH), filed a Form 4.
- The filing reports the acquisition of 110,732 stock options on June 3, 2024, with an exercise price of $1.28.
- The options vest over a one-year period in equal quarterly installments and expire on June 3, 2034.
- Lisjak directly owns 110,732 derivative securities following the reported transaction.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard regulatory filing indicating an officer's acquisition of stock options, which can be seen as a positive but doesn't guarantee future performance.
Positives
- The acquisition of stock options by a company officer can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a company officer may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/03/2024 | Date of earliest transaction (acquisition of stock options) |
| 06/03/2024 | Date of stock option grant |
| 06/03/2034 | Expiration date of the stock options |
| 06/05/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.